10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Worldwide legislative challenges related to psychoactive drugs

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Abstract

          The discovery of a “new” psychoactive substance is a relatively exceptional event, while the regulatory response usually involved the assessment of risks to public health and inclusion of the novel substance in the national list of controlled substances. However, in recent years we have witnessed the rapid emergence of new chemical substances, which elude international control and pose a challenge to existing processes and a threat to the credibility of control systems. We currently review and present characteristics of these legal and illegal new substances and issues regarding their global monitoring and regulatory measures already taken, or in the process of being taken, for their control. The concept of prohibition applied in active substance-related legislation is rather hazard ridden as balance is required between the ban on substances of potential therapeutic use and the access on the market of high-risk substances.

          Graphical Abstract

          Current and future laws regarding psychoactive compounds.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: not found
          • Book: not found

          World Drug Report 2016

          (2016)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Controlling new drugs under marketing regulations.

            The rapid emergence of myriad substances openly marketed as 'legal highs' is straining traditional drug control systems which require time and basic scientific data on harms to react, presenting governments with the dilemma of no response or a disproportionate response. Some countries have side-stepped this using novel policy and legislative approaches. Should other countries consider them?
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Generic legislation of new psychoactive drugs.

              New psychoactive drugs (NPDs, new psychoactive substances) enter the market all the time. However, it takes several months to ban these NPDs and immediate action is generally not possible. Several European countries and drug enforcement officers insist on a faster procedure to ban NPDs. Introduction of generic legislation, in which clusters of psychotropic drugs are banned in advance, has been mentioned as a possible solution. Here we discuss the pros and cons of such an approach. First, generic legislation could unintentionally increase the expenditures of enforcement, black market practices, administrative burden and health risks for users. Second, it may have a negative impact on research and the development of new treatments. Third, due to the complexity of generic legislation, problems in the enforcement are anticipated due to lack of knowledge about the chemical nomenclature. Finally, various legal options are already available to ban the use, sale and trade of NPDs. We therefore conclude that the currently used scientific benefit-risk evaluation should be continued to limit the adverse health effects of NPDs. Only in emergency cases, where fatal incidents (may) occur, should this approach be overruled.
                Bookmark

                Author and article information

                Contributors
                carolina.negrei@outlook.com
                +40769609893 , bianca.galateanu@bio.unibuc.ro
                g_miriana@yahoo.com
                dr.balalau@gmail.com
                sciencecontactemailmlbd@gmail.com
                erenozcagli@gmail.com
                cfenga@unime.it
                kovatsi@hotmail.com
                domnikif@hotmail.com
                tsatsaka@uoc.gr
                Journal
                Daru
                Daru
                DARU Journal of Pharmaceutical Sciences
                BioMed Central (London )
                1560-8115
                2008-2231
                2 June 2017
                2 June 2017
                2017
                : 25
                : 14
                Affiliations
                [1 ]ISNI 0000 0000 9828 7548, GRID grid.8194.4, Departament of Toxicology, , Faculty of Pharmacy, “Carol Davila” University of Medicine and Pharmacy, ; Bucharest, Romania
                [2 ]ISNI 0000 0001 2322 497X, GRID grid.5100.4, Department of Biochemistry and Molecular Biology, , University of Bucharest, ; 91-95 Spl. Independenței, 050095 Bucharest, Romania
                [3 ]Department of Surgery, “Sf. Pantelimon” Emergency Clinical Hospital, Bucharest, Romania
                [4 ]Bucharest Bar Association, Romanian Lawyers Union, Bucharest, Romania
                [5 ]ISNI 0000 0001 2166 6619, GRID grid.9601.e, Department of Pharmaceutical Toxicology, , Faculty of Pharmacy, Istanbul University, ; Beyazit, 34116 Istanbul, Turkey
                [6 ]ISNI 0000 0001 2178 8421, GRID grid.10438.3e, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Occupational Medicine Section, , University of Messina, ; 98125 Messina, Italy
                [7 ]ISNI 0000000109457005, GRID grid.4793.9, Laboratory of Forensic Medicine and Toxicology, , School of Medicine, Aristotle University of Thessaloniki, ; Thessaloniki, Greece
                [8 ]ISNI 0000 0004 0576 3437, GRID grid.8127.c, , University of Crete, Medical School, Department of Toxicology and Forensic Sciences, ; Heraklion, Greece
                Article
                180
                10.1186/s40199-017-0180-2
                5455135
                8b869c43-8da2-41fe-9a25-2c79cc899085
                © The Author(s). 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 14 December 2016
                : 11 May 2017
                Categories
                Review Article
                Custom metadata
                © The Author(s) 2017

                Pharmacology & Pharmaceutical medicine
                “new” psychoactive substances,regulatory,control systems,legislation

                Comments

                Comment on this article